Key Stats for Intuitive Surgical Stock
- Current Price: $482.22
- Target Price (Mid): ~$814
- Street Target: ~$577
- Potential Total Return: ~69%
- Annualized IRR: ~12% / year
- Earnings Reaction: +7.16% (April 22, 2026)
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Intuitive Surgical (ISRG) entered its Q1 2026 report under pressure. In March, the FDA issued a safety alert after Intuitive recalled its 8mm SureForm 30 Gray Reload curved-tip stapler, linked to four serious injuries and one patient death. Earlier in the quarter, a cyber incident resulted in unauthorized access to some customer and employee data.
CFO Jamie Samath addressed it directly on the call, confirming it did not disrupt operations or materially affect Q1 results. The stock had been grinding near multi-month lows.
The April 21 report changed the conversation. Revenue rose 23% to $2.77 billion, beating consensus by nearly 6%. Non-GAAP EPS came in at $2.50, up 38% year-over-year and around 19% above analyst estimates. The stock surged 7.16% the following day.
The beat was broad-based. Total procedures grew 17%, with da Vinci procedures up 16% and Ion procedures, the company’s robotic lung biopsy platform, up 39%. The non-GAAP operating margin reached 39% on the strength of fixed-cost leverage, and recurring revenue accounted for 86% of total sales.
The quarter also cleared one key concern: da Vinci 5 reached contribution margins comparable to the prior-generation Xi system, removing a bear-case item that had lingered since the platform launched.
CEO David Rosa framed it simply on the call: “Q1 was a solid start to the year for Intuitive, driven by 17% total procedure growth and broad-based adoption across da Vinci and Ion.”
Management followed by raising full-year da Vinci procedure growth guidance to 13.5% to 15.5% and lifting gross margin guidance to 67.5% to 68.5%.
See historical and forward estimates for Intuitive Surgical stock (It’s free!) >>>
Is Intuitive Surgical Undervalued Today?
At $482.22, ISRG trades at roughly 45x next twelve months earnings and about 31x NTM EV/EBITDA. The multiple has already compressed from over 60x a year ago, and at current levels, there is limited room for error.
The bull case rests on what kind of revenue is growing, not just how fast.
CFO Samath introduced the phrase “innovation-led revenue growth” to describe something specific: revenue grew 23% in Q1 while procedures grew only 17%. That six-point gap reflects higher per-procedure pricing from da Vinci 5 and a richer mix of single-port SP procedures.
Samath’s explanation was direct: “Where you can be differentiated and make a meaningful difference for customers, then you get to sharing that value in the form of accretive pricing.”
That gap has room to widen. Da Vinci 5, now in nearly 1,500 installed systems used by almost 13,000 surgeons, generates approximately 11% higher utilization than the Xi it replaces. More than half of all Q1 system placements were da Vinci 5. As the installed base continues shifting to the newer platform, per-procedure revenue and free cash flow both compound without requiring a record system-placement quarter to do it.
The risks are real. China was below the corporate average in Q1 due to low tender activity, domestic competition, and pricing pressure, and management does not expect clarity on new reimbursement codes there until 2027.
GLP-1 drugs are suppressing bariatric procedures, which declined approximately 10% in Q1. Tariffs are expected to weigh on gross margins by around 100 basis points for the full year, with higher freight and semiconductor memory costs building in the second half. ACA subsidy changes add further uncertainty to U.S. procedure volumes.
What holds the thesis together is the recurring revenue structure. At 86% of quarterly sales, instruments, accessories, and service revenue compound as utilization rises, insulating the business from lumpy system-placement cycles.
See how Intuitive Surgical performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $482.22
- Target Price (Mid): ~$814
- Potential Total Return: ~69%
- Annualized IRR: ~12% / year
See analysts’ growth forecasts and price targets for Intuitive Surgical stock (It’s free!) >>>
The TIKR mid-case model uses a revenue CAGR of approximately 12% through 12/31/30, driven by continued procedure volume growth across da Vinci and Ion and the accretive pricing dynamic Samath described on the call. The net income margin assumption of approximately 32% reflects operating leverage from recurring revenue, and the da Vinci 5 contribution margin normalization confirmed in Q1.
Japan is the clearest near-term catalyst. Japan’s Ministry of Health, Labor and Welfare introduced reimbursement for seven new robotic procedures and incremental support for high-volume programs, both effective June 2026. If that converts to measurable OUS procedure acceleration, it removes one of the main overhangs on the international thesis. China is the primary model risk: persistent domestic competition and low tender activity beyond 2027 would pressure the OUS growth rate that underpins the 12% CAGR assumption. The model also gives zero credit to the AI and digital capabilities that CEO Rosa outlined on the call, including augmented anatomy identification and telesurgery. Those represent optionality above the mid-case.
At $482.22, the stock sits about 20% below its 52-week high of $603.88 and around 16% below the Street’s mean target of approximately $577. The Street currently shows 16 Buys, 7 Outperforms, 9 Holds, 1 Underperform, and 1 Sell among 34 analysts. For the mid-case model to break down, Intuitive would need to grow revenue well below its own three-year historical CAGR of around 17% while seeing simultaneous margin compression. Q1 2026 gave little reason to expect either.
Conclusion
Watch the Q2 2026 report on July 21. The metric that matters most is OUS procedure growth, specifically, whether Japan shows sequential acceleration after the June reimbursement changes take effect. That is the binary management flagged as the clearest near-term catalyst, and it will tell investors whether the international recovery is real or still pending.
Intuitive Surgical is compounding procedure volume, recurring revenue, and per-procedure pricing simultaneously. Q1 2026 is the clearest evidence yet that the da Vinci 5 transition is ahead of schedule.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Intuitive Surgical?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Intuitive Surgical, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Intuitive Surgical alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Intuitive Surgical on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
